Browsing: steady

Amgen Inc. (ISIN US0311621009) stock is trading close to its recent level in mid-August 2026 as investors weigh a higher analyst price target against a strategic reset in the company’s obesity drug pipeline, highlighted on August 17, 2026 by new industry reporting. One recent note lifted the 12?month price objective on Amgen shares to $380,…

Amgen stock sits at the intersection of mature biologic franchises and a broad late-stage pipeline that is increasingly focused on oncology and cardiometabolic diseases. The California-based biotechnology group Amgen Inc. (ISIN US0311621009) combines steady cash generation from legacy drugs such as Enbrel and Prolia with new assets in cancer and obesity, giving investors a blend…

Amgen Inc. (ISIN US0311621009) stock sits in the large-cap pharma bracket with investors closely watching how recent double-digit revenue growth and the integration of Horizon Therapeutics translate into future earnings power. In 2023 Amgen reported revenue of roughly $28.2 billion, up around 7% from about $26.3 billion in 2022, while the company continued to return…

Funding for cyber charter schools will remain steady this year, even as Pennsylvania’s newest school code refines and builds on existing reform policies aimed at keeping students safe and holding cyber schools accountable

Kerry stock offers investors a way to participate in long-term global demand for taste, nutrition, and functional food ingredients. The Irish group Kerry Group plc (ISIN IE0004906560) has built a broad portfolio of technologies that support large food and beverage manufacturers as they respond to shifting consumer preferences, regulatory standards, and sustainability expectations. As a…